沙美特罗替卡松粉吸入治疗COPD稳定期患者疗效观察

目的探讨联合吸入沙美特罗替卡松粉(50/500μg)治疗稳定期中重度慢性阻塞性肺疾病(COPD)患者的临床疗效。方法 60例中重度COPD患者随机分为试验组和对照组各30例,试验组吸入沙美特罗替卡松粉吸入剂(50/500μg),每次1吸,每日2次;对照组口服茶碱缓释剂,每12小时口服1次,每次0.2g,治疗3个月,痰液黏稠时加用盐酸氨溴索口服液10mL,每日3次口服。根据圣.乔治呼吸问卷的方法对临床症状问卷及体征检查评分,并评估肺功能变化。结果试验组与对照组比较,临床症状积分,肺功能指标的改善差异有统计学意义(P<0.05)。结论吸入沙美特罗替卡松粉吸入剂(50/500μg)能改善稳定期中重度COPD患者的临床症状和肺功能。

Clinical Observation of Inhaled Salmeterol/Fluticasone Propionate in Patients with Stable Moderate/Severe COPD

Objective To evaluate the clinical effects of inhaled salmeterol/fluticasone propionate(50/500 μg)in patients with stable moderate/severe chronic obstructive pulmonary disease(COPD).Methods Patients with moderate-severe COPD(n= 60)were randomly divided into treatment group and control group.The control patients took slow-release theophylline 0.2 g twice daily for 3 month and expectorants(ambroxol hydrochloride 10ml three times daily)when necessary.Patients in treatment group received salmeterol/fluticasone(50/500 μg)propionate inhalation twice daily via Turbuhaler for 3 months.Before and after the therapeutic course,pulmonary function tests in patients of both groups were performed and compared.According to the standard grade of St George′s respiratory disease questionnaire(SGRQ),the clinical symptoms and physical signs were evaluated.Results At the end of the study,the values of FEV1,FEV1/FVC,and FEV1/predictive value in treatment group after treatment were significantly higher than those in control group(P<0.05),whereas the value of SGRQ in treatment group was lower than that before treatment(P<0.05).Conclusion Inhaled salmeterol 50 μg and fluticasone propionate 500 μg could significantly improve the pulmonary function and clinical symptoms of patients with stable moderate to severe COPD.